Weight changes with depot neuroleptic maintenance therapy

Acta Psychiatrica Scandinavica

Volumn 59, Issue 5, 1979, Pages 525-528

  Johnson, D A W ^a   Breen, M ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

anti parkinsonian drugs; continues 2 years; dose; Flupenthixol decanoate; fluphenazine decanoate maintenance therapy; significant weight gain; unrelated; weight change

Indexed keywords

ANTIPARKINSON AGENT; FLUPENTIXOL; FLUPHENAZINE; NEUROLEPTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADVERSE DRUG REACTION; BODY WEIGHT; CENTRAL NERVOUS SYSTEM; DRUG THERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; MAINTENANCE THERAPY; SCHIZOPHRENIA; THERAPY;

BODY WEIGHT; DECANOATES; DELAYED-ACTION PREPARATIONS; FLUPENTHIXOL; FLUPHENAZINE; HUMAN; PROSPECTIVE STUDIES; SCHIZOPHRENIA; TIME FACTORS;

EID: 0018421122     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1979.tb00252.x     Document Type: Article

References (8)

1. The depot fluphenazines ‐ A re‐appraisal after 10 years clinical experience
2. Drug‐produced obesity. Experiences with chlorpromazine, perphenazine and clopenthixol
3. Pipothiazine in schizophrenia
4. Pimozide and fluphenazine decanoate in continuation therapy
5. The long‐acting phenothiazines
6. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia